Home | Structured Search | Drug Resource
Find: within
West Nile Virus Disease > Diagnosis Author: Amy V. Bode, MD, MSPH; James J. Sejvar, MD; Anthony A. Marfin, MD, MPH
Editorial changes - 2009-06-03
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Muscle weakness, including acute flaccid paralysis, and changes in mental status in patients with encephalitis are predictors of death and poor neurologic outcome.

Evidence:

  • Only 28% of patients with WNV encephalitis and/or neuromuscular weakness in a Canadian series were discharged home without additional support, and most had persistent neurologic deficits 30 days after discharge (29).
  • Three out of 16 hospitalized, WNV antibody-positive patients had poliomyelitis-like acute flaccid paralysis in a 2002 Louisiana series (30).

Comments:

  • Case-fatality rates among patients hospitalized with neuroinvasive WNV illness during recent outbreaks of the currently circulating strain of WNV in the U.S., Canada, and Israel have ranged from 12% to 18%. These case-fatality rates are greater than those previously seen in the Middle East and Africa. This may be due to differences in the age structure or frequency of medical risk factors in the nonimmune population or to the underlying virulence of the WNV strain. Although the specific reason is not known, there has been a much higher incidence of encephalitis and a higher case-fatality rate than seen in previous outbreaks (6; 31).
  • Case-fatality rates have been shown to be higher among patients under age 50 and in those with more severe disease (2; 24; 26).

FAQs
Amy V. Bode, MD, MSPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Anthony A. Marfin, MD, MPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. James J. Sejvar, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Yanlin Tang, PhD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.